Gary Corrigan

Collaborative commercial leader with dedication to partnering with coworkers to promote an engaged, empowering work culture. Documented strengths in building and maintaining relationships with a diverse range of internal and external stakeholders to reach and exceed set targets. Recognized on several occasions for delivering record-breaking revenue and profit gains within highly competitive markets.

• Windows package
• Internal budget and tracking programs
• Administrator in several CRM systems and tools
• Digital communication systems

• Cox SW, Corrigan G, Palmer S. Inhibition of azidothymidine triphosphate of RT from paired AZT-susceptible and resistant isolates of HIV-1. Antivir Chem Chemotherapy. 1995 6(2), 123-6.
• Awad RJ, Corrigan GE, Ekstrand DH, Thorstensson R, Kallander CF, Gronowitz JS. Measurement of levels of human immunodeficiency virus type 1 reverse transcriptase (RT) and RT activity-blocking antibody in human serum by a new standardized colorimetric assay. J Clin Microbiol. 1997 May;35(5):1080-9
• Corrigan GE, Al-Khalili L, Malmsten A, Thorstensson R, Fenyo EM, Kallander CF, Gronowitz JS. Differences in reverse transcriptase activity versus p24 antigen detection in cell culture, when comparing a homogeneous group of HIV type 1 subtype B viruses with a heterogeneous group of divergent strains. AIDS Res Hum Retroviruses. 1998 Mar 1;14(4):347-52
• Braun J, Plantier JC, Hellot MF, Tuaillon E, Gueudin M, Damond F, Malmsten A, Corrigan GE, Simon F. A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes. AIDS. 2003 Feb 14;17(3):331-6
• Malmsten A, Shao XW, Aperia K, Corrigan GE, Sandstrom E, Kallander CF, Leitner T, Gronowitz JS. HIV-1 viral load determination based on reverse transcriptase activity recovered from human plasma. J Med Virol. 2003 Nov;71(3):347-59
• Tuaillion E, Gueudin M, Lemée V, Gueit I, Roques P, Corrigan GE, Plantier J-C, Simon F, Braun J. Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. JAIDS, 2004, Vol 37, 5, 1543-9
• Greengrass VL, Turnbull SP, Hocking J, Dunne AL, Tachedjian G, Corrigan GE and Crowe SM. Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring, J Curr HIV Res. 2005, 3, 183-190
• Jennings C, Fiscus SA, Crowe SM, Danilovic AD, Morack RJ, Scianna S, Cachafeiro A, Brambilla DJ, Schupbach J, Dunne A, Stevens W, Respess R, Oliviero E. Varnier OE, Corrigan GE, Gronowitz JS, Ussery MA, and Bremer JW. Comparison of Two HIV RNA Surrogate Assays to the standard HIV RNA Assay. J Clin Micro, 2005, 5950-5956
• Lombart JP, Vray M, Kafando A, Lemée V, Ouédraogo-Traoré R, Corrigan GE, Plantier JC, Simon F and Braun J. Evaluation of plasma virion reverse transcriptase activity and heat-dissociated-boosted p24 assay for HIV load monitoring in Burkina Faso, West Africa. AIDS, 2005, 12, 19(12), 1273-7
• Gary E Corrigan, Eva Olausson Hansson, Andreas Mörner, Neil Berry, Clas FR Källander and Rigmor Thorstensson. Reverse transcriptase viral load correlates with RNA in SIV/SHIV infected macaques, AIDS Res Hum Retroviruses, 2006, 22, 9, 917-23
• Basson AE, Ntsala M, Martinson N, Tlale E, Corrigan GE, Shao X, Gray G, McIntyre J, Puren A, Morris L. Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):538-43